Showing results (11-20 of 292) with videos related to
Sort By:
Pageof 30
Science Translational Medicine|December 18, 2015
Comment on "Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity" and "Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination"Scott B HalsteadUrolithiasis|November 13, 2015
Epidemiology of bladder stone of children: precipitating eventsScott B HalsteadAnnals of the New York Academy of Sciences|September 16, 2009
Antibodies determine virulence in dengueScott B HalsteadRevista Panamericana De Salud Publica = Pan American Journal of Public Health|March 8, 2007
Dengue in the Americas and Southeast Asia: do they differ?Scott B HalsteadPaediatrics and International Child Health|June 7, 2012
Controversies in dengue pathogenesisScott B HalsteadEmerging Infectious Diseases|March 22, 2017
Biologic Evidence Required for Zika Disease Enhancement by Dengue AntibodiesScott B HalsteadClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 31, 2021
Is Dengue Vaccine Protection Possible?Scott B HalsteadVaccine|October 15, 2017
Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of ageScott B HalsteadThe Lancet. Infectious Diseases|July 17, 2017
Achieving safe, effective, and durable Zika virus vaccines: lessons from dengueScott B HalsteadPageof 30